Progress of post-transplant lymphoproliferative disorder after pediatric liver transplantation

doi:10.3877/cma.j.issn.1674-3903.2022.03.009

Abstract

Abstract:

Liver transplantation is the only treatment for children with end-stage liver disease. Advances in surgical techniques and immunosuppressive agents have greatly improved the recipients′ prognosis after liver transplantation. Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication after pediatric liver transplantation. It is closely related to the level of immunosuppression and Epstein-Barr virus DNA replication load in pediatric recipients after liver transplantation. There are certain difficulties in the diagnosis and treatment of PTLD, and the prognosis of the recipients is poor. This article reviews the recent research progress on PTLD following pediatric liver transplantation.

Key words: Pediatric liver transplantation, Post-transplant lymphoproliferative disorder, Progress

Dan Shi, Zhigang Gao. Progress of post-transplant lymphoproliferative disorder after pediatric liver transplantation[J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(03): 174-178.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2022.03.009

https://zhyzzz.cma-cmc.com.cn/EN/Y2022/V16/I03/174

References 48

1	Qin T, Gu XQ, Jeong SS, et al. Impact of EBV infection and immune function assay for lymphoproliferative disorder in pediatric patients after liver transplantation: a single-center experience[J]. Hepatobiliary Pancreat Dis Int, 2020，19(1)：3-11.
2	Wang T, Feng M, Luo C, et al. Successful treatment of pediatric refractory Burkitt lymphoma PTLD after liver transplantation using anti-CD19 chimeric antigen receptor T-cell therapy[J]. Cell Transplant, 2021，30：963689721996649.
3	陈奥，练巧燕，张建恒，等. 移植后淋巴增殖性疾病研究进展[J/CD]. 中华移植杂志：电子版，2021，15(5): 307-312.
4	Caillard S, Porcher R, Provot F, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score[J]. J Clin Oncol, 2013，31(10)：1302-1309.
5	Tajima T, Hata K, Haga H, et al. Post-transplant lymphoproliferative disorders after liver transplantation: a retrospective cohort study including 1954 transplants[J]. Liver Transpl, 2021，27(8)：1165-1180.
6	Wasuwanich P, Batsis I, Thawillarp S, et al. Post-transplant eosinophilic gastrointestinal disorders and lymphoproliferative disorder in pediatric liver transplant recipients on tacrolimus[J]. Transpl Immunol, 2021，68：101438.
7	Baker A, Frauca Remacha E, Torres Canizales J, et al. Current practices on diagnosis, prevention and treatment of post-transplant lymphoproliferative disorder in pediatric patients after solid organ transplantation: results of ERN Transplant Child Healthcare Working Group Survey[J]. Children (Basel), 2021，8(8)：661.
8	Éboli LPCB, Tannuri ACA, Tannuri U. Seropositivity for cytomegalovirus and PCR-EBV monitoring: protective factors for posttransplant lymphoproliferative disorder in pediatric liver transplant[J]. Pediatr Transplant, 2022，26(4)：e14226.
9	Akbas A, Tiede C, Lemound J, et al. Post-transplant lymphoproliferative disorders with naso- and oropharyngeal manifestation[J]. Transpl Int, 2015，28(11)：1299-1307.
10	Walti LN, Mugglin C, Sidler D, et al. Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): a nationwide cohort study[J]. Am J Transplant, 2021，21(7)：2532-2542.
11	Kampers J, Orjuela-Grimm M, Schober T, et al. Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules [J]. Leuk Lymphoma, 2017，58(3)：633-638.
12	刘静怡，孙丽莹，朱志军，等. 儿童肝移植后淋巴组织增生性疾病诊疗分析[J/CD]. 实用器官移植电子杂志，2021，9(3): 183-189.
13	Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders[J]. Arch Pathol Lab Med, 2007, 131(8)：1209-1218.
14	Ghigna MR, Reineke T, Rincé P, et al. Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders[J]. Pathobiology, 2013，80(2)：53-59.
15	Opelz G, Daniel V, Naujokat C, et al. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma[J]. Transplantation, 2009，88(8)：962-967.
16	Dharnidharka VR, Lamb KE, Gregg JA, et al. Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States[J]. Am J Transplant, 2012，12(4)：976-983.
17	Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults[J]. N Engl J Med, 2018，378(6)：549-562.
18	Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients[J]. Transplantation, 2000，70(1)：94-99.
19	Chardot C, Nicoluzzi JE, Janssen M, et al. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation[J]. Transplantation, 2001，71(2)：224-229.
20	Sindhi R, Webber S, Venkataramanan R, et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus[J]. Transplantation, 2001，72(5)：851-855.
21	Kwong AJ, Fix OK. Update on the management of the liver transplant patient[J]. Curr Opin Gastroenterol, 2015，31(3)：224-232.
22	Kremers WK, Devarbhavi HC, Wiesner RH, et al. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival[J]. Am J Transplant, 2006，6(5 Pt 1)：1017-1024.
23	Zimmermann T, Hoppe-Lotichius M, Tripkovic V, et al. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for post-transplant lymphoproliferative disease (PTLD) [J]. Eur J Intern Med, 2010，21(3)：208-215.
24	Hézode C, Duvoux C, Germanidis G, et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation[J]. Hepatology, 1999，30(3)：775-778.
25	Kinch A, Baecklund E, Backlin C, et al. A population-based study of 135 lymphomas after solid organ transplantation: the role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival[J]. Acta Oncol, 2014，53(5)：669-679.
26	Zhang A, Zhang M, Shen Y, et al. Hepatitis B virus reactivation is a risk factor for development of post-transplant lymphoproliferative disease after liver transplantation[J]. Clin Transplant, 2009，23(5)：756-760.
27	Panagiotidis E, Quigley AM, Pencharz D, et al. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder[J]. Leuk Lymphoma, 2014，55(3)：515-519.
28	Aguilera N, Gru AA. Reexamining post-transplant lymphoproliferative disorders: newly recognized and enigmatic types[J]. Semin Diagn Pathol, 2018，35(4)：236-246.
29	Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation[J]. N Engl J Med, 1982，306(15)：913-918.
30	Green M, Kaufmann M, Wilson J, et al. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children[J]. Clin Infect Dis, 1997，25(6)：1344-1349.
31	Jarasvaraparn C, Choudhury S, Rusch C, et al. Characteristics, risk factors, and outcomes of neutropenia after liver or kidney transplantation in children[J]. Pediatr Transplant, 2022，26(1)：e14131.
32	Trappe R, Riess H, Anagnostopoulos I, et al. Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone[J]. Ann Hematol, 2009，88(2)：167-172.
33	Lindsay J, Othman J, Heldman MR, et al. Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes[J]. Curr Opin Infect Dis, 2021，34(6)：635-645.
34	Chen HS, Ho MC, Hu RH, et al. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation[J]. J Formos Med Assoc, 2019，118(9)：1362-1368.
35	McDiarmid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients[J]. Transplantation, 1998，66(12)：1604-1611.
36	Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients[J]. Am J Transplant, 2005，5(9)：2222-2228.
37	Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder[J]. Transplantation, 2008，86(2)：215-222.
38	Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS Guidelines[J]. Br J Haematol, 2010，149(5)：693-705.
39	Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients[J]. Transplantation, 2001，71(8)：1076-1088.
40	Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder[J]. Am J Transplant, 2011，11(2)：336-347.
41	Trappe RU, Dierickx D, Zimmermann H, et al. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase Ⅱ trial [J]. J Clin Oncol, 2017，35(5)：536-543.
42	Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial[J]. Lancet Oncol, 2012，13(2)：196-206.
43	Dang BN, Ch′ng J, Russell M, et al. Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T-cell therapy[J]. Pediatr Transplant, 2021，25(5)：e13861.
44	Perica K, Varela JC, Oelke M, et al. Adoptive T cell immunotherapy for cancer[J]. Rambam Maimonides Med J, 2015，6(1)：e0004.
45	Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation[J]. N Engl J Med, 1994，330(17)：1185-1191.
46	Dharnidharka VR, Mohanakumar T. New approaches to treating B-cell cancers induced by Epstein-Barr virus[J]. N Engl J Med, 2015，372(6)：569-571.
47	陶媛，汝昆. 移植后淋巴组织增殖性疾病的诊疗特点及进展[J/CD]. 实用器官移植电子杂志，2019, 7(5): 401-405.
48	Mumtaz K, Faisal N, Marquez M, et al. Post-transplant lymphoproliferative disorder in liver recipients: characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations[J]. Can J Gastroenterol Hepatol, 2015，29(8)：417-422.

[1]	Yongbo Zhang, Liang Zhang, Liuyang Chen, Rui Dai, Hua Sun, Sheng Yang, Bo Meng, Qing Peng. Mitochondrial and intervertebral disc degeneration [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(03): 265-269.
[2]	Yijun Fan, Feng Yang, Wei Wang, Heying Yin, Jun Liu. Research progress in the diagnostic and therapeutic value of Delphian lymph node metastasis in papillary thyroid carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(04): 306-310.
[3]	Xiyan Zheng, Zheng Zhou, Fangping He, Zhiqun Lin, Fei Du, Qin Xie, Shaoping Wang, Xianjie Shi. Risk factors for the prognosis of metabolic syndrome and hepatitis B virus related hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(02): 104-109.
[4]	Mingzhu Huang, Ying Lu, Kang He, Yan Wang. Investigation and analysis of medication compliance of pediatric liver transplant recipients after discharge [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(02): 112-117.
[5]	Huiling Long, Mi Lin, Ting Shao. Research progress and application of three-dimensional spherical mesenchymal stem cell culture technology [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 229-234.
[6]	Fuhao Qin, Zheng Zheng, Bin Jiang. Research progress of mesenchymal stem cells in the treatment of perianal fifistulizing Crohn's disease [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(03): 172-177.
[7]	Chen Cai, Wei Gong. Current application and outlook of immunotherapy for bile duct neoplasms [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(02): 162-166.
[8]	Bing Lan, Huaiming Wang, Hui Wang, Bo Ma. Research progress on locally advanced colon cancer with bladder invasion [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 505-511.
[9]	Jiafa Ren, Buyun Wu, Changying Xing, Huijuan Mao. Advances in the basic and clinical research on acute kidney injury in 2022 [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(05): 276-281.
[10]	Jiawei He, Liang Zhang, Qi Yang, Zhanxiang Wang. Current status of diagnosis and treatment of progressive hemorrhagic injury after traumatic brain injury [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2023, 09(03): 175-179.
[11]	Hengyu Luan, Xiaoyong Sai. Treatment status and research progress of post-traumatic stress disorder [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2023, 09(02): 112-118.
[12]	Kunqi Zhang, Rui Zhang, Jia Xu, Qinglin Kang. The progress of the management of floating knee injury [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2023, 09(04): 252-256.
[13]	Qiang Ma, Jun Li, Lijuan Gou. Expression levels of miR-21-3p and RUNX3 in severe acute pancreatitis and their predictive value to the progression of the disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 337-341.
[14]	Wenpeng Huang, Yongkang Qiu, Qi Yang, Lele Song, Zhao Chen, Yan Fan, Lei Kang. Research progress of PET related radiomics in tumor prognosis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(02): 104-110.
[15]	Yihan Wu, Zhang Lei, Hongda Lu. Progress in understanding of role of MUC16/CA125 in diagnosis and treatment of benign and malignant tumors [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 591-595.

Please choose a citation manager

Content to export